NEWS
-
News & Events
- Founder and Chairman , Professor Hiroaki Shimokawa, presented to the regular meeting of the Tokyo South Rotary Club.
- March 7, 2025
- Founder, Chairman & CMO, Professor Hiroaki Shimokawa, delivered a lecture at a special symposium at nano tech 2025.se
- January 31, 2025
-
Papers & Conferences
- Founder, Chairman & CMO, Professor Hiroaki Shimokawa, delivered a lecture at a special symposium at nano tech 2025.se
- January 31, 2025
-
Media
- An article about our ultrasound treatment for Alzheimer’s disease was published in Pharmaceutical Economics Web.
- November 10, 2023
-
Press Releases
- Sound Wave Innovation Announces New Leadership to Ensure the Deployment of Dementia Treatment
- April 1, 2025
- Founder and Chairman , Professor Hiroaki Shimokawa, presented to the regular meeting of the Tokyo South Rotary Club.
- March 7, 2025
COMPANY
Our target is to make our innovative medical devices spreading all over the world and provide better therapies for patients.
Technical Information
-
LIPUS
The molecular mechanisms of the LIPUS therapy include mechano-transduction mediated by β1-integrin/caveolin-1 with resultant upregulation of endothelial NO synthase(eNOs) and vascular endothelial growth factor(VEGF). It enhances angiogenesis in ischemic tissue and induces spontaneous improvement of microcirculatory disorder for both severe angina and mild dementia. Two pipelines are in clinical study.
-
SWCS
Comparing to the ablation catheter that has been used for the treatment of arrhythmia, SWCS could treat deeper Arrhythmia source with less surface / peripheral tissues damage and less Thrombus formation.